PARP1 and lung carcinoma: Significantly, tumors with mutations in the DNA repair protein PTEN account for 4–8% of all NSCLCs and it has been shown that PTEN mutant tumor cells are sensitive to PARP inhibitors, expanding the number of lung cancer patients this therapy may benefit (113, 114).